Serum OX40 Level in Patients with Neuromyelitis Optica

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Immunology, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Professor, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Neuromyelitis Optica (NMO) is an autoimmune inflammatory disease of the central nervous system (CNS), disturbing spinal cord and optic nerves specified by the presence of pathogenic serum autoantibodies against aquaporin 4 (AQP4) in the majority of patients . The role of T-cell is ambiguous. OX40 (CD134) is member of the tumor necrosis factor receptor family and is expressed selectively on activated T lymphocytes which increases in several autoimmune diseases. The aim of the study was to evaluate serum OX40 levels in patients with NMO.Methods: The study involved 19 patients with NMO and 19 controls. Serum OX40 levels were determined by the enzyme-linked immunosorbent assay (ELISA).Findings: The present study showed no significant different between OX40 levels in the serum of patients with NMO compared with controls (P = 0.378). Serum level of OX40 in women were lower than men (P = 0.470). In addition, we found that median serum OX40 levels in AQP4 Ab-serpositive were higher than seronegative NMO patient but was not statistically significant (P = 0.410).Conclusion: Serum OX40 levels could not be used as a diagnostic or treatment marker for NMO.

Keywords

References

  1. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BA, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 2012; 72(1): 53-64.
  2. Matsuya N, Komori M, Nomura K, Nakane S, Fukudome T, Goto H, et al. Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica. Int Immunol 2011; 23(9): 565-73.
  3. Lalan S, Khan M, Schlakman B, Penman A, Gatlin J, Herndon R. Differentiation of neuromyelitis optica from multiple sclerosis on spinal magnetic resonance imaging. Int J MS Care 2012; 14(4): 209-14.
  4. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 2012; 69(9): 1176-80.
  5. Pereira WL, Reiche EM, Kallaur AP, Kaimen-Maciel DR. Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review. J Neurol Sci 2015; 355(1-2): 7-17.
  6. Flanagan EP, Weinshenker BG. Neuromyelitis optica spectrum disorders. Curr Neurol Neurosci Rep 2014; 14(9): 483.
  7. Uzawa A, Mori M, Hayakawa S, Masuda S, Nomura F, Kuwabara S. Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica. BMC Neurol 2010; 10: 113.
  8. Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 2014; 176(2): 149-64.
  9. Li Y, Wang H, Long Y, Lu Z, Hu X. Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2011; 234(1-2): 155-60.
  10. Yan J, Chen G, Gong J, Wang C, Du R. Upregulation of OX40-OX40 ligand system on T lymphocytes in patients with acute coronary syndromes. J Cardiovasc Pharmacol 2009; 54(5): 451-5.
  11. Pohl M, Kawakami N, Kitic M, Bauer J, Martins R, Fischer MT, et al. T cell-activation in neuromyelitis optica lesions plays a role in their formation. Acta Neuropathol Commun 2013; 1: 85.
  12. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009; 9(4): 271-85.
  13. Redmond WL, Ruby CE, Weinberg AD. The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol 2009; 29(3): 187-201.
  14. Taylor L, Schwarz H. Identification of a soluble OX40 isoform: development of a specific and quantitative immunoassay. J Immunol Methods 2001; 255(1-2): 67-72.
  15. Flynn S, Toellner KM, Raykundalia C, Goodall M, Lane P. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J Exp Med 1998; 188(2): 297-304.
  16. Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, et al. Signaling through OX40 enhances antitumor immunity. Semin Oncol 2010; 37(5): 524-32.
  17. Xiaoyan Z, Pirskanen R, Malmstrom V, Lefvert AK. Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis. Clin Exp Immunol 2006; 143(1): 110-6.
  18. Carboni S, Aboul-Enein F, Waltzinger C, Killeen N, Lassmann H, Pena-Rossi C. CD134 plays a crucial role in the pathogenesis of EAE and is upregulated in the CNS of patients with multiple sclerosis. J Neuroimmunol 2003; 145(1-2): 1-11.
  19. Komura K, Yoshizaki A, Kodera M, Iwata Y, Ogawa F, Shimizu K, et al. Increased serum soluble OX40 in patients with systemic sclerosis. J Rheumatol 2008; 35(12): 2359-62.
  20. Ilzecka J. Serum soluble OX40 in patients with amyotrophic lateral sclerosis. Acta Clin Croat 2012; 51(1): 3-7.
  21. Laustsen JK, Rasmussen TK, Stengaard-Pedersen K, Horslev-Petersen K, Hetland ML, Ostergaard M, et al. Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis. Arthritis Res Ther 2014; 16(5): 474.
Journal of Isfahan Medical School
Volume 34, Issue 386 - Serial Number 386
May and June 2016
Pages 657-662

Files

History

  • Receive Date: 12 April 2016
  • Revise Date: 26 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics